CD274 and differentiated thyroid carcinoma: More recently, in a phase 1b study, Mehnert et al. reported that the anti-PD-L1 antibody, pembrolizumab, may have an antitumor activity with an acceptable safety profile in a small percentage of advanced differentiated thyroid cancer patients (28).